Multiple sclerosis (MS) is a lifelong condition affecting the brain and spinal cord (the central nervous system). In MS, the immune system mistakenly attacks the protective myelin sheath that surrounds nerve fibres, causing inflammation and damage that disrupts signals between the brain and the body. Around 130,000 people in the UK are living with MS, making it one of the most common neurological conditions to affect young adults. MS is typically diagnosed between the ages of 20 and 40, and is approximately two to three times more common in women than in men.
MS is unpredictable — its course varies enormously from person to person. Some people experience mild symptoms that barely affect daily life, while others can develop significant disability over time. This guide explains the types of MS, symptoms, diagnosis, NHS treatments, and how to live well with the condition.
What Causes MS?
MS is an autoimmune disease, meaning the immune system attacks the body’s own tissue. In MS, immune cells mistakenly target myelin — the fatty insulating material that surrounds and protects nerve fibres in the central nervous system. When myelin is damaged or destroyed (a process called demyelination), nerve signals slow down, become distorted, or cannot pass at all. Over time, the nerve fibres themselves can also be damaged, leading to permanent neurological changes.
The exact cause of MS is not fully understood, but it is thought to result from a combination of genetic susceptibility and environmental triggers. Having a first-degree relative with MS increases your risk threefold. Low vitamin D levels, Epstein-Barr virus (EBV) infection, smoking, and obesity during adolescence have all been linked to increased MS risk. MS is more common at higher latitudes, further from the equator, where sun exposure and vitamin D synthesis are lower.
Types of Multiple Sclerosis
Relapsing Remitting MS (RRMS)
Around 85% of people with MS are initially diagnosed with relapsing remitting MS. RRMS is characterised by episodes of new or worsening symptoms (relapses or attacks) followed by periods of partial or complete recovery (remissions). During remissions, symptoms may disappear entirely or leave residual deficits. Relapses typically develop over hours or days and last for at least 24 hours, usually resolving over weeks to months.
Secondary Progressive MS (SPMS)
Many people with RRMS will eventually transition to secondary progressive MS, in which disability accumulates steadily over time, with or without ongoing relapses. The transition is often gradual and not always clearly defined. Better disease-modifying treatments are helping delay this transition for many people diagnosed today.
Primary Progressive MS (PPMS)
Around 10–15% of people are diagnosed with primary progressive MS from the outset. In PPMS, disability accumulates from the beginning without distinct relapses or remissions. PPMS tends to be diagnosed at an older age (typically in the 40s and 50s) and is equally common in men and women. Ocrelizumab (Ocrevus) is the first and only NICE-approved disease-modifying therapy for PPMS in the UK.
Clinically Isolated Syndrome (CIS)
CIS refers to a first episode of neurological symptoms lasting at least 24 hours and caused by inflammation or demyelination in the central nervous system. It is not yet MS but may develop into MS if further episodes occur or if MRI shows lesions consistent with MS. Some people who experience CIS are offered early treatment to reduce the risk of conversion to MS.
Symptoms of MS
MS can affect almost any part of the nervous system, making its symptoms extremely varied. Different people experience different combinations of symptoms, and these can change over time. Common symptoms include:
- Fatigue: Experienced by around 80% of people with MS, this is often the most disabling symptom. MS fatigue is distinct from ordinary tiredness and is not relieved by sleep.
- Vision problems: Optic neuritis (inflammation of the optic nerve) causes blurred vision, eye pain, or temporary vision loss and is often an early symptom. Double vision (diplopia) can also occur.
- Numbness and tingling: Pins and needles, numbness, or a sensation of tightness or a band around the torso (known as the “MS hug”) are common.
- Muscle weakness and spasticity: Weakness in the limbs, stiffness, and muscle spasms are frequently reported.
- Balance and coordination problems: Unsteady walking, dizziness, and tremor can develop.
- Bladder and bowel problems: Urgency, frequency, incontinence, and constipation affect the majority of people with MS at some point.
- Pain: Both neuropathic pain (nerve-related) and musculoskeletal pain are common.
- Cognitive difficulties: Problems with memory, concentration, and mental processing speed (sometimes called “cog fog”) affect up to 65% of people.
- Depression and anxiety: Mental health conditions are significantly more common in people with MS than in the general population, and are partly driven by the psychological impact of the diagnosis and partly by neurological changes.
- Speech and swallowing difficulties: Less common but can occur, particularly in advanced MS.
- Lhermitte’s sign: A characteristic electric shock sensation that runs down the spine when the neck is flexed forward.
Uhthoff’s Phenomenon
Many people with MS notice that symptoms worsen temporarily when body temperature rises — during exercise, hot weather, fever, or a hot bath. This is called Uhthoff’s phenomenon and occurs because heat slows or blocks nerve conduction in already-damaged fibres. Importantly, it does not represent a new relapse or permanent damage; symptoms typically resolve when temperature returns to normal.
Diagnosing MS
There is no single test for MS. Diagnosis is based on the McDonald Criteria, which require evidence of lesions in the central nervous system that are disseminated in space (affecting multiple areas) and disseminated in time (occurring at different points). This requires the integration of clinical history, neurological examination, and investigations.
MRI Scanning
MRI is the most important diagnostic tool for MS. It can detect demyelinating lesions in the brain and spinal cord with high sensitivity. Gadolinium-enhanced MRI can distinguish active (new or enlarging) lesions from older ones. Most people with MS have a characteristic pattern of lesions on MRI, and the scan can also monitor disease activity and treatment response over time.
Other Tests
A lumbar puncture (spinal tap) may be performed to analyse cerebrospinal fluid for oligoclonal bands — proteins indicating inflammation in the CNS, present in around 90% of people with MS. Evoked potentials (visual, auditory, or somatosensory) measure how quickly nerve signals travel and can detect subclinical demyelination. Blood tests are also done to rule out other conditions that can mimic MS.
NHS Treatment for MS
There is currently no cure for MS, but substantial advances in treatment have transformed outcomes over the past two decades. NHS treatment for MS focuses on three areas: managing relapses, slowing disease progression with disease-modifying therapies (DMTs), and treating symptoms.
Treating Relapses
Significant relapses are typically treated with a short course of high-dose corticosteroids (usually methylprednisolone, given intravenously or orally for three to five days). Steroids reduce inflammation and speed up recovery from a relapse but do not alter the underlying course of the disease or prevent future relapses.
Disease-Modifying Therapies (DMTs)
DMTs reduce the frequency and severity of relapses and help slow the accumulation of disability. The NHS offers a wide range of DMTs for eligible patients with active RRMS, now classified broadly as moderate-efficacy and high-efficacy treatments.
Moderate-efficacy DMTs available on the NHS include beta-interferons (Avonex, Rebif, Betaferon, Extavia), glatiramer acetate (Copaxone), dimethyl fumarate (Tecfidera), and teriflunomide (Aubagio). These are typically used for milder active disease and are generally administered by injection or taken orally.
High-efficacy DMTs include natalizumab (Tysabri), ocrelizumab (Ocrevus), ofatumumab (Kesimpta), cladribine (Mavenclad), and alemtuzumab (Lemtrada). These offer greater suppression of disease activity but carry higher risks and require closer monitoring. Ocrelizumab is also the only NICE-approved DMT for primary progressive MS. The NHS now follows an active treatment approach, offering highly effective DMTs earlier in the disease course for many patients.
Stem cell transplantation (haematopoietic stem cell transplantation or HSCT) — sometimes called the “Aberdeen procedure” — is available at a small number of NHS centres for selected patients with highly active, aggressive RRMS. It is not suitable for everyone but has produced remarkable outcomes in carefully chosen candidates.
Symptom Management
Managing individual symptoms is a core part of MS care. Fatigue can be addressed through energy conservation strategies, amantadine, or modafinil (in some cases). Spasticity is treated with baclofen, tizanidine, gabapentin, or physiotherapy — and for severe cases, intrathecal baclofen pumps or Sativex (nabiximols, a cannabis-derived spray). Bladder symptoms are managed with medications such as oxybutynin or solifenacin, intermittent self-catheterisation, or referral to a continence service. Neuropathic pain is treated with amitriptyline, gabapentin, or pregabalin. Depression is managed with antidepressants and psychological therapy (CBT is particularly effective). Physiotherapy, occupational therapy, and speech and language therapy play vital roles in maintaining function and independence.
Living with MS
An MS diagnosis is life-changing, but most people with MS continue to live full and active lives for many years. Regular review by an MS specialist nurse and neurologist is important. An MS care plan should cover disease monitoring, medication reviews, symptom management, mental health support, employment advice, and practical support at home.
Exercise is safe and beneficial for people with MS and can help manage fatigue, spasticity, mood, and strength. A physiotherapist experienced in neurological conditions can design an appropriate programme. Heat avoidance strategies (cooling vests, exercising in cool environments, staying hydrated) can help manage Uhthoff’s phenomenon.
The MS Society (www.mssociety.org.uk) and the MS Trust (www.mstrust.org.uk) provide extensive information, helplines, and community support. The MS Society helpline is available on 0808 800 8000. PIP (Personal Independence Payment) and other disability benefits may be available depending on how MS affects daily living and mobility.
Pregnancy and MS
MS does not generally affect fertility. Interestingly, relapse rates typically fall during pregnancy — particularly in the third trimester — due to natural immune modulation, before often rising again in the three to six months postpartum (the rebound period). Most DMTs must be stopped before conception, and planning is essential with your MS team. Despite this, the majority of women with MS have healthy pregnancies and can breastfeed successfully.
Key Takeaways
- MS affects around 130,000 people in the UK and is most commonly diagnosed in adults aged 20–40
- It is an autoimmune disease in which the immune system attacks the myelin sheaths protecting nerve fibres
- The most common type is relapsing remitting MS (RRMS), affecting around 85% of those diagnosed
- Symptoms are highly variable but frequently include fatigue, vision problems, numbness, weakness, and bladder issues
- Diagnosis is based on the McDonald Criteria using MRI, clinical history, and other tests
- NHS disease-modifying therapies (DMTs) reduce relapse rates and slow progression — with a growing move towards early high-efficacy treatment
- Symptom management, physiotherapy, and mental health support are all important parts of MS care
- The MS Society (0808 800 8000) and MS Trust provide free support and information
Related Health Guides on YourHealthXpert
Explore these related NHS-aligned health guides:
- Parkinson’s Disease Guide — Both MS and Parkinson’s are progressive neurological conditions; understand the NHS support pathways and how they differ in mechanism and treatment.
- Dementia & Alzheimer’s Guide — Cognitive changes can occur in advanced MS; learn about NHS neuropsychological support and how to distinguish MS cognitive symptoms from dementia.
- Anxiety & Depression Guide — Depression affects over half of people with MS and is directly linked to disease activity; learn about NHS mental health support integrated with neurology care.
- Osteoporosis Guide — Reduced mobility from MS and corticosteroid use for relapses significantly increase fracture risk; understand NHS bone protection strategies in MS.
- Rheumatoid Arthritis Guide — Both MS and RA are autoimmune conditions; learn about the overlapping biologics used across inflammatory neurological and joint diseases.
- Lupus Guide — Lupus can cause neurological symptoms that mimic MS; understand how NHS neurologists differentiate between autoimmune neurological conditions.